RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Voyager Therapeutics Stock

Voyager Therapeutics EBIT 2025

Voyager Therapeutics EBIT

-131.05 M USD

Ticker

VYGR

ISIN

US92915B1061

WKN

A143XJ

In 2025, Voyager Therapeutics's EBIT was -131.05 M USD, a 62.82% increase from the -80.49 M USD EBIT recorded in the previous year.

The Voyager Therapeutics EBIT history

YEAREBIT (undefined USD)
2030e-
2029e-182.9
2028e-127.46
2027e-136.69
2026e-126.28
2025e-131.05
2024-80.49
2023122.01
2022-50.8
2021-73.6
202027.4
2019-51.7
2018-91.1
2017-71.9
2016-41.3
2015-20.3
2014-14.4
2013-3.8

Voyager Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Voyager Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Voyager Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Voyager Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Voyager Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Voyager Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Voyager Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Voyager Therapeutics’s growth potential.

Voyager Therapeutics Revenue, EBIT and net profit per share

DateVoyager Therapeutics RevenueVoyager Therapeutics EBITVoyager Therapeutics Net Income
2030e105.16 M undefined0 undefined-50 M undefined
2029e77.81 M undefined-182.9 M undefined-67.41 M undefined
2028e108.08 M undefined-127.46 M undefined-14.9 M undefined
2027e72.93 M undefined-136.69 M undefined-87.48 M undefined
2026e70.47 M undefined-126.28 M undefined-98.49 M undefined
2025e39.4 M undefined-131.05 M undefined-124.48 M undefined
202480 M undefined-80.49 M undefined-65 M undefined
2023250.01 M undefined122.01 M undefined132.33 M undefined
202240.9 M undefined-50.8 M undefined-46.4 M undefined
202137.4 M undefined-73.6 M undefined-71.2 M undefined
2020171.1 M undefined27.4 M undefined36.7 M undefined
2019104.4 M undefined-51.7 M undefined-43.6 M undefined
20187.6 M undefined-91.1 M undefined-88.3 M undefined
201710.1 M undefined-71.9 M undefined-70.7 M undefined
201614.2 M undefined-41.3 M undefined-40.2 M undefined
201517.3 M undefined-20.3 M undefined-38.3 M undefined
20140 undefined-14.4 M undefined-17.7 M undefined
20130 undefined-3.8 M undefined-3.8 M undefined

Voyager Therapeutics stock margins

The Voyager Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Voyager Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Voyager Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Voyager Therapeutics's sales revenue. A higher gross margin percentage indicates that the Voyager Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Voyager Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Voyager Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Voyager Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Voyager Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Voyager Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Voyager Therapeutics Margin History

Voyager Therapeutics Gross marginVoyager Therapeutics Profit marginVoyager Therapeutics EBIT marginVoyager Therapeutics Profit margin
2030e0 %0 %-47.54 %
2029e0 %-235.07 %-86.63 %
2028e0 %-117.93 %-13.79 %
2027e0 %-187.42 %-119.95 %
2026e0 %-179.2 %-139.76 %
2025e0 %-332.65 %-315.97 %
20240 %-100.61 %-81.25 %
20230 %48.8 %52.93 %
20220 %-124.21 %-113.45 %
20210 %-196.79 %-190.37 %
20200 %16.01 %21.45 %
20190 %-49.52 %-41.76 %
20180 %-1,198.68 %-1,161.84 %
20170 %-711.88 %-700 %
20160 %-290.85 %-283.1 %
20150 %-117.34 %-221.39 %
20140 %0 %0 %
20130 %0 %0 %

Voyager Therapeutics Aktienanalyse

What does Voyager Therapeutics do?

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Voyager Therapeutics's EBIT

Voyager Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Voyager Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Voyager Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Voyager Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Voyager Therapeutics stock

How much did Voyager Therapeutics achieve in EBIT for the current year?

In the current year, Voyager Therapeutics has achieved an EBIT of -131.05 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Voyager Therapeutics.

How has the EBIT of Voyager Therapeutics developed in recent years?

The EBIT of Voyager Therapeutics has increased by 62.818% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Voyager Therapeutics?

The EBIT of Voyager Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 6/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2025.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 6/27/2025.

What was the dividend of Voyager Therapeutics in the year 2024?

In the year 2024, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Voyager Therapeutics

Our stock analysis for Voyager Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Voyager Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.